

Brucellosis Vaccine Market Forecasts to 2034 – Global Analysis By Vaccine Type (DNA Vaccine, Subunit Vaccine and Other Vaccine Types), Disease (Viral Diseases, Bacterial Vaccines and Other Diseases), Distribution Channel, Application, End User and By Geography

<https://marketpublishers.com/r/B1159B02FD06EN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: B1159B02FD06EN

Abstracts

According to Statistics MRC, the Global Brucellosis Vaccine Market is accounted for \$290.8 million in 2026 and is expected to reach \$488.8 million by 2034 growing at a CAGR of 6.70% during the forecast period. The Brucellosis vaccine is a preventive measure against Brucella bacteria, which cause brucellosis—a zoonotic disease affecting animals and humans. The vaccine is primarily administered to livestock such as cattle, goats, and sheep, as these animals are common reservoirs for the bacteria. The vaccine helps control the spread of brucella infections, reducing the risk of transmission to humans through contact with contaminated animal products or direct contact with infected animals.

According to the report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022.

Market Dynamics:

Driver:

Prevalence of brucellosis

With Brucellosis posing substantial health and economic threats globally, particularly in regions with close human-animal interaction, the demand for effective vaccines has risen. Governments, livestock owners, and healthcare authorities are increasingly recognizing the importance of prevention through vaccination to control the spread of Brucellosis. This heightened awareness, coupled with a growing need for sustainable agricultural practices, fuels the expansion of the brucellosis vaccine market as stakeholders actively seek and invest in innovative vaccine solutions to mitigate the impact of this infectious disease.

Restraint:

Antimicrobial treatment options

Antimicrobial treatment options play a crucial role in the restraint of the Brucellosis vaccine market. Antibiotics such as doxycycline and rifampin are essential for managing and treating the infection in humans. This reliance on antimicrobial therapies may hinder the growth of the Brucellosis vaccine market, as effective drugs can provide immediate relief and may reduce the perceived need for preventive vaccination. Additionally, challenges in developing a universally effective brucellosis vaccine further emphasize the significance of antimicrobial treatments in addressing the current burden of the disease.

Opportunity:

Growing livestock industry

As the demand for meat and dairy products rises globally, livestock farmers are keen on ensuring the health and productivity of their herds. Brucellosis can cause reproductive issues in cattle and sheep, leading to economic losses in the industry. The development and widespread adoption of effective Brucellosis vaccines offer a preventive solution, reducing the prevalence of the disease and promoting overall livestock well-being. This presents a lucrative market for vaccine manufacturers, as farmers increasingly prioritize disease management to enhance the sustainability and profitability of their livestock operations.

Threat:

Limited awareness and education

The limited awareness and education threat in the Brucellosis vaccine market arises from insufficient knowledge and understanding among stakeholders, including healthcare professionals and the public. This lack of awareness may hinder the adoption of brucellosis vaccines, leading to lower vaccination rates. Inadequate education about the severity of brucellosis and the benefits of vaccination can contribute to an underestimation of the disease's impact, potentially impeding efforts to control its spread. Addressing this threat requires targeted educational campaigns to enhance awareness among healthcare providers, policymakers, and the general population.

Covid-19 Impact:

The diversion of resources and focus towards combating the global health crisis has led to a slowdown in the development, production, and distribution of brucellosis vaccines. Research and investment priorities have shifted, affecting the overall progress and availability of vaccines for Brucellosis. Additionally, disruptions in supply chains and logistical challenges have further hindered vaccine accessibility. As efforts continue to address COVID-19, the Brucellosis vaccine market faces delays and uncertainties, potentially affecting the control of this bacterial infection in both human and animal populations.

The viral diseases segment is expected to be the largest during the forecast period

The viral diseases segment is experiencing notable growth due to increasing awareness and efforts to combat this bacterial infection. And encompassing innovative research and development targeting *Brucella* strains, has witnessed a surge in investment and advancements. Furthermore, this growth is driven by a collaborative approach between pharmaceutical companies, research institutions, and governmental initiatives to address the significant public health concern posed by brucellosis.

The animal care centers segment is expected to have the highest CAGR during the forecast period

The Animal Care Centers segment is experiencing notable growth due to increasing awareness and proactive measures taken to control the spread of brucellosis in animals. With a rising emphasis on animal health and welfare, veterinary clinics and care centers are actively incorporating brucellosis vaccination programs into their services. This surge is also driven by regulatory efforts to mitigate the economic and public health impacts of brucellosis. Additionally, as livestock and companion animal

owners seek preventive solutions, the demand for brucellosis vaccines within animal care centers is expanding.

Region with largest share:

North America dominated the global market and is expected to retain its position during the forecast period. Potential factors contributing to growth includes increased awareness about brucellosis prevention, rising demand for livestock health management, and government initiatives promoting animal health. The region's advanced veterinary healthcare infrastructure and research capabilities also foster the development and adoption of brucellosis vaccines. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

Region with highest CAGR:

The Asia Pacific is estimated to grow at a considerable growth rate in the market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Increasing demand for dairy and meat products, coupled with a surge in animal husbandry practices, has fueled the need for effective vaccines.

Key players in the market

Some of the key players in Brucellosis Vaccine market include Biogenesis-Bago, Biovet, Boehringer Ingelheim, Calier, Ceva Sante Animale, Colorado Serum, CZ Veterinaria, Hester Biosciences, Indian Immunologicals, Onderstepoort Biological, Qilu, SYVA Laboratorios, Technovax and Zoetis.

Key Developments:

In January 2024, Ceva Sant? Animale, acquired US-based Scout Bio, a biotech company focused on pet therapies. The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will

enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Vaccine Types Covered:

DNA Vaccine

Subunit Vaccine

Inactivated

Live Attenuated

mRNA Vaccines

Vector Vaccine

Viral vector vaccines

Other Vaccine Types

Diseases Covered:

Viral Diseases

Bacterial Vaccines

Allergy Vaccines

Cancer Vaccines

Other Diseases

Distribution Channels Covered:

Hospital & Retail Pharmacies

Government Suppliers

Other Distribution Channels

Applications Covered:

Cattle

Goat

Horses

Sheep

Swine

Other Applications

End Users Covered:

Veterinary Hospitals & Clinics

Animal Care Centers

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL BRUCELLOSIS VACCINE MARKET, BY VACCINE TYPE

- 5.1 Introduction
- 5.2 DNA Vaccine
- 5.3 Subunit Vaccine
 - 5.3.1 Conjugate Vaccines
 - 5.3.2 Recombinant vaccines
 - 5.3.3 Toxoid vaccines
- 5.4 Inactivated
- 5.5 Live Attenuated
- 5.6 mRNA Vaccines
- 5.7 Vector Vaccine
- 5.8 Viral vector vaccines
- 5.9 Other Vaccine Types

6 GLOBAL BRUCELLOSIS VACCINE MARKET, BY DISEASE

- 6.1 Introduction
- 6.2 Viral Diseases
 - 6.2.1 Covid-19
 - 6.2.2 Hepatitis
 - 6.2.3 Herpes Zoster
 - 6.2.4 Human Papilloma Virus
 - 6.2.5 Measles, Mumps, and Rubella
 - 6.2.6 Influenza
 - 6.2.7 Rotavirus
 - 6.2.8 Other Viral Diseases
- 6.3 Bacterial Vaccines
 - 6.3.1 Diphtheria Pertussis Tetanus
 - 6.3.2 Pneumococcal Diseases
 - 6.3.3 Meningococcal Diseases
 - 6.3.4 Other Bacterial Vaccines
- 6.4 Allergy Vaccines
- 6.5 Cancer Vaccines
- 6.6 Other Diseases

7 GLOBAL BRUCELLOSIS VACCINE MARKET, BY DISTRIBUTION CHANNEL

- 7.1 Introduction

- 7.2 Hospital & Retail Pharmacies
- 7.3 Government Suppliers
- 7.4 Other Distribution Channels

8 GLOBAL BRUCELLOSIS VACCINE MARKET, BY APPLICATION

- 8.1 Introduction
- 8.2 Cattle
- 8.3 Goat
- 8.4 Horses
- 8.5 Sheep
- 8.6 Swine
- 8.7 Other Applications

9 GLOBAL BRUCELLOSIS VACCINE MARKET, BY END USER

- 9.1 Introduction
- 9.2 Veterinary Hospitals & Clinics
- 9.3 Animal Care Centers
- 9.4 Other End Users

10 GLOBAL BRUCELLOSIS VACCINE MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India

- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa
 - 10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 Biogenesis-Bago
- 12.2 Biovet
- 12.3 Boehringer Ingelheim
- 12.4 Calier
- 12.5 Ceva Sante Animale
- 12.6 Colorado Serum
- 12.7 CZ Veterinaria
- 12.8 Hester Biosciences
- 12.9 Indian Immunologicals
- 12.10 Onderstepoort Biological
- 12.11 Qilu
- 12.12 SYVA Laboratorios
- 12.13 Technovax

12.14 Zoetis

List Of Tables

LIST OF TABLES

Table 1 Global Brucellosis Vaccine Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Brucellosis Vaccine Market Outlook, By Vaccine Type (2023-2034) (\$MN)

Table 3 Global Brucellosis Vaccine Market Outlook, By DNA Vaccine (2023-2034) (\$MN)

Table 4 Global Brucellosis Vaccine Market Outlook, By Subunit Vaccine (2023-2034) (\$MN)

Table 5 Global Brucellosis Vaccine Market Outlook, By Conjugate Vaccines (2023-2034) (\$MN)

Table 6 Global Brucellosis Vaccine Market Outlook, By Recombinant vaccines (2023-2034) (\$MN)

Table 7 Global Brucellosis Vaccine Market Outlook, By Toxoid vaccines (2023-2034) (\$MN)

Table 8 Global Brucellosis Vaccine Market Outlook, By Inactivated (2023-2034) (\$MN)

Table 9 Global Brucellosis Vaccine Market Outlook, By Live Attenuated (2023-2034) (\$MN)

Table 10 Global Brucellosis Vaccine Market Outlook, By mRNA Vaccines (2023-2034) (\$MN)

Table 11 Global Brucellosis Vaccine Market Outlook, By Vector Vaccine (2023-2034) (\$MN)

Table 12 Global Brucellosis Vaccine Market Outlook, By Viral vector vaccines (2023-2034) (\$MN)

Table 13 Global Brucellosis Vaccine Market Outlook, By Other Vaccine Types (2023-2034) (\$MN)

Table 14 Global Brucellosis Vaccine Market Outlook, By Disease (2023-2034) (\$MN)

Table 15 Global Brucellosis Vaccine Market Outlook, By Viral Diseases (2023-2034) (\$MN)

Table 16 Global Brucellosis Vaccine Market Outlook, By Covid-19 (2023-2034) (\$MN)

Table 17 Global Brucellosis Vaccine Market Outlook, By Hepatitis (2023-2034) (\$MN)

Table 18 Global Brucellosis Vaccine Market Outlook, By Herpes Zoster (2023-2034) (\$MN)

Table 19 Global Brucellosis Vaccine Market Outlook, By Human Papilloma Virus (2023-2034) (\$MN)

Table 20 Global Brucellosis Vaccine Market Outlook, By Measles, Mumps, and Rubella (2023-2034) (\$MN)

- Table 21 Global Brucellosis Vaccine Market Outlook, By Influenza (2023-2034) (\$MN)
- Table 22 Global Brucellosis Vaccine Market Outlook, By Rotavirus (2023-2034) (\$MN)
- Table 23 Global Brucellosis Vaccine Market Outlook, By Other Viral Diseases (2023-2034) (\$MN)
- Table 24 Global Brucellosis Vaccine Market Outlook, By Bacterial Vaccines (2023-2034) (\$MN)
- Table 25 Global Brucellosis Vaccine Market Outlook, By Diphtheria Pertussis Tetanus (2023-2034) (\$MN)
- Table 26 Global Brucellosis Vaccine Market Outlook, By Pneumococcal Diseases (2023-2034) (\$MN)
- Table 27 Global Brucellosis Vaccine Market Outlook, By Meningococcal Diseases (2023-2034) (\$MN)
- Table 28 Global Brucellosis Vaccine Market Outlook, By Other Bacterial Vaccines (2023-2034) (\$MN)
- Table 29 Global Brucellosis Vaccine Market Outlook, By Allergy Vaccines (2023-2034) (\$MN)
- Table 30 Global Brucellosis Vaccine Market Outlook, By Cancer Vaccines (2023-2034) (\$MN)
- Table 31 Global Brucellosis Vaccine Market Outlook, By Other Diseases (2023-2034) (\$MN)
- Table 32 Global Brucellosis Vaccine Market Outlook, By Distribution Channel (2023-2034) (\$MN)
- Table 33 Global Brucellosis Vaccine Market Outlook, By Hospital & Retail Pharmacies (2023-2034) (\$MN)
- Table 34 Global Brucellosis Vaccine Market Outlook, By Government Suppliers (2023-2034) (\$MN)
- Table 35 Global Brucellosis Vaccine Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)
- Table 36 Global Brucellosis Vaccine Market Outlook, By Application (2023-2034) (\$MN)
- Table 37 Global Brucellosis Vaccine Market Outlook, By Cattle (2023-2034) (\$MN)
- Table 38 Global Brucellosis Vaccine Market Outlook, By Goat (2023-2034) (\$MN)
- Table 39 Global Brucellosis Vaccine Market Outlook, By Horses (2023-2034) (\$MN)
- Table 40 Global Brucellosis Vaccine Market Outlook, By Sheep (2023-2034) (\$MN)
- Table 41 Global Brucellosis Vaccine Market Outlook, By swine (2023-2034) (\$MN)
- Table 42 Global Brucellosis Vaccine Market Outlook, By Other Applications (2023-2034) (\$MN)
- Table 43 Global Brucellosis Vaccine Market Outlook, By End User (2023-2034) (\$MN)
- Table 44 Global Brucellosis Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2023-2034) (\$MN)

Table 45 Global Brucellosis Vaccine Market Outlook, By Animal Care Centers
(2023-2034) (\$MN)

Table 46 Global Brucellosis Vaccine Market Outlook, By Other End Users (2023-2034)
(\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Brucellosis Vaccine Market Forecasts to 2034 – Global Analysis By Vaccine Type (DNA Vaccine, Subunit Vaccine and Other Vaccine Types), Disease (Viral Diseases, Bacterial Vaccines and Other Diseases), Distribution Channel, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/B1159B02FD06EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B1159B02FD06EN.html>